Deals
Eli Lilly kicked off a pivotal 2026 campaign with a multi-year collaboration with current partner Nimbus Therapeutics worth a potential $1.3 billion for a preclinical obesity therapeutic. The deal follows a 2022 partnership struck by the companies to target the AMPK protein in cardiometabolic diseases.
FEATURED STORIES
2026 is set to be a banner year for M&A in biopharma, as buyers facing major patent cliffs fight for a small pool of late-stage assets.
Metsera showed the biopharma world that M&A is back. Who could be next?
These deals radically reshaped the biopharma world, either by one vaccine rival absorbing another, a Big Pharma doubling down after another failed acquisition or, in the case of Pfizer and Novo, two heavyweights duking it out over a hot obesity biotech.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Flexion Therapeutics, Inc. and Xenon Pharmaceuticals Inc. announced that the companies have entered into a definitive agreement that provides Flexion with the global rights to develop and commercialize XEN402, a NaV1.7 inhibitor, for the management of post-operative pain.
Lightcast Discovery Ltd announces that it has raised £1.3 m in seed financing from private investors to develop the capabilities and applications of its platform including continuing to expand its range of pilot studies.
4BIO Ventures II fund solely focused on advanced therapies targeting $150 million final close
ADC Therapeutics SA announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its common shares.
There are high hopes for more M&A in the industry for the remainder of the year. Here’s a look at the 10 top takeover targets.
When Eli Lilly and Company acquired Loxo Oncology for $8 billion, the company was gambling on several pipeline drugs in oncology.
Purdue Pharma may file for bankruptcy this week after negotiations over a multi-billion opioid claims settlement have stalled, multiple sources are reporting.
To accelerate development and commercialisation of innovative Glaucoma MIGS device, MINIjectTM
The Board of Directors of Cardea Bio and the Board of Directors of Nanosens Innovations have each authorized the respective companies to proceed with a proposed business combination.
Bordeaux, France, September 05th 2019 – LNC Therapeutics, a French biotech company specializing in gut microbiome-based drug discovery, announced that it has raised €6.2 million via a capital increase and non-dilutive funding.